Figure 6 | Cell Death & Disease

Figure 6

From: Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogs

Figure 6

The efficacy of CYD-6-17 in RCC tumor in vivo. (a) The experimental therapy of CYD-6-17 using ALZET osmotic pumps to deliver 10 mg/kg of drug for 7 days in 786-0 KD subcutaneous xenograft model. Both tumor volume measured by caliper and tumor weight of control or treatment group were depicted. *P<0.05. (b) Immunohistochemistry staining of PDPK1, Ki-67 (proliferation marker), cleaved caspase-3 (apoptosis marker) and p27 (cell cycle arrest marker) in RCC tumors. Quantitative data were shown in the right panel. (c) The total body weight of animal from control and treatment group. (d) A schematic presentation of the mechanism of CYD-6-17 in targeting PDPK1 and its downstream pathways in drug-resistant RCC

Back to article page